Member Info for itsallamess

Some nice big trades / buys today...

If shares got so low on AiM surely lago would start buying from the naz and selling back?

Either way the less availible shares the price would go up!

When we list on the US stock exchange I'm sure they will be given a bunch of new shares to buy... ohhh... this could be where they get funds for clevegen progress...

Funding for hibiscus is sorted.. k6.1 million, if more cash is needed I think it will be when we get positive results and then it could be a partnership, or possibly more uS grant money. I'm not worried about the path of Traumakine forvthe foreseeable future.

Clevegen... we will need more money at some point... but from markus response to the loaded question, out seems very close to announcing a II of some sort investing in us.

Much prefer this than a general placing... adds confidence. Remember we already have the swedish pension fund aboard.

I find a few developments quite I interesting. Obviously it's hard for a small pharma to get ahead of big pharma and their agendas.

Liked marku comment on the interview about the WHO, its proved inyected interferon doesnt work... has this had an impact on the reason for the 6.1 million investment for Traumakine? Our form of interferon beta administration is the only way for flooded lungs ARdS

We also know the issue with steroids which is a fixed opinion that steroids are the only treatment for ARDS by some... but in other interviews marku has said ther is a place and time for both treatments to work. which brings us to the new patent application:

"Faron has also applied for new patent protection relating to the induction of CD73 for organ protection, followed by the use of steroids for the treatment of systemic inflammation"

"we believe that this sequential administration of intravenous interferon beta, before corticosteroids, could become a standard of care in the future and as such have filed a patent application to protect the commercial opportunity"

If there is one thing I've learned from dragons den is that a patent lights the eyes up of investors

How the new II investors been named?

(Pause) Errr no... Grin

Not a partner but investors... Starting to think raising more cash for clevegen will be private placing with someone big! Any thoughts?

To be fair I was disappointed yesteday to see the SP dip back in to the 3s..

Nice RNS to steady the boat

Interesting point I wasn't aware of:
'There have been no innovative new drugs in the field of emergency care for decades..'

What's the deal, currently 375

The new discovery of the role of soluble Clever-1 as an immune suppressive molecule is striking, indicating the soluble part of this receptor could cause systemic inhibition of T-cells in all locations of body, therefore controlling the general immune capacity in cancer patients. We hope to be able to overcome this inhibition just by increasing the dosing frequency of bexmarilimab to provide maximal binding and the removal of Clever-1 from body fluids and tissues, including tumours.”

Just re watched the interview from yesteday.

Partners for clevegen. Seems we know know what is needed to get a partner on board.

Anyone who understands this or who can correct me would be appreciated (I think this is correct but could be wrong)

T cells kill cancer.

When t cells look for cancers to kill the identify them by their lack of a identifying mark. This mark is clever 1.

If a tumor has a clever 1 mark it leaves it alone.

What cancer tomors have done is be able to adapt by using clever 1 to trick tells into thinking they are not cancer!

Now we introduce clevegen which instructs the tcell to see beyond the trick cancer cells are doing.

Now for the issue... For some reason cancer paints blood plasma the trys to flush out clevegen by increasing the clever 1 receptor...

So now the test is to increase the dose of Clevegen from a 3 week dose to 1 or 2 weeks.

this is a very significant finding and soon and explains why we are waiting for a partner but as soon as results are in the the partners who are circling will make their iffers

Long

Do yourself a favor and don't become one of those posters who sold out a now comes back to complain...

Still time to get back in before we double during H1

What new info will be released?

Us listing! I don't know what's involved in getting listed but it seems the process is quite involved, but it's good to hear they have been and are working on it.

Dan.. Us listing and your mortgage is paid!

Just watched the interview..

Very excited here.

Who was Tommy? Some good questions from him!

Nice to that markku felt the WHO never treated them right... he said he felt angry by how the have acted and wont even give the data of what they found!

Will watch again tomorrow but what stood out...? We have 3 blockbuster treatments!

Zens back!

https://youtu.be/myZLPrF7rrY

Fair dues to greenman for trading, we all are here to make some money and have a discussion.

I've been here a long time and been involved in the discussions and many others have, but I suppose on the day I sell out or sell some I might mention it here... I hope I'm not a subject of abuse!

However greenman, sell your EUA share and load up :)

Number of AIMSecurities in issue

46,896,747 ordinary shares
(30 Nov 2020)

The Company does not hold any shares in treasury.

The percentage of AIM securities not in public hands (as defined by the AIM rules)

22.38%

Certain early Pre-IPO investors* hold a significant amount of Company's shares, with a total of

49.32%

71.70% of shares are tied up

28.30% of shares are in the freefloat
Just over 15 million ish

46,896,747 ordinary shares

The percentage of AIM securities not in public hands (as defined by the AIM rules)

22.38%

Certain early Pre-IPO investors* hold a significant amount of Company's shares, with a total of

49.32%

So we have 71.70% of the shares are tied up. Leaving 28.30% of the shares in the freefloat.

Hardly any shares in the freefloat, Just over 15 million shares that can be traded

Would the phase 'cancer cure' be too early to utter out loud?!

Markku Jalkanen, said: “Never during my career have I seen that a high baseline count of regulatory T cells (Tregs) predicts a good response to a therapy